Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy

被引:28
|
作者
Sarihan, S [1 ]
Ercan, I
Saran, A
Çetintas, SK
Akalin, H
Engin, K
机构
[1] Uludag Univ, Fac Med, Dept Radiat Oncol, TR-16059 Bursa, Turkey
[2] Uludag Univ, Fac Med, Dept Biostat, TR-16059 Bursa, Turkey
[3] AOS Oncol Hosp, Dept Radiat Oncol, Bursa, Turkey
[4] Uludag Univ, Fac Med, Dept Microbiol & Infect Dis, TR-16059 Bursa, Turkey
来源
CANCER DETECTION AND PREVENTION | 2005年 / 29卷 / 02期
关键词
non-small cell lung cancer; radiotherapy; infection; predisposing factors;
D O I
10.1016/j.cdp.2004.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We aim to determine infections occuring in patients with non-small cell lung cancer during radiotherapy (RT). Methods and materials: A total of 181 patients had been treated with thoracic radiotherapy between October 1995 and December 1999. Radiotherapy was given using 1.8-3 Gray (Gy) fraction daily, five fractions a week for a total dose of 59.4 Gy (30-70.2 Gy). A complete history was collected retrospectively for each patient. All microbiological examinations were performed according to the routine procedures of the hospital laboratory. Numeric and categoric variables were employed such as sex, age, performance status, histology, stage, chemotherapy, usage of corticosteroids, neutropenia, surgery, hospitalization, associated diseases, smoking during treatment, package per year of cigarette smoking, dose of radiotherapy, and response rates. Results: Infections developed in 84 patients (46%, 84/181) during thoracic radiotherapy. A 101 episodes of infections developed in these patients. Most patients suffered from sputum production (65%), cough (59%), auscultation findings (31%) and fever (31%). Gram-negative bacteria were the most frequently isolated pathogens in the cultures of specimens (70%, 16/23 samples). Neoadjuvant chemotherapy (OR = 4.81; 95% CI, 1.57-9.12; p = 0.003) and neutropenia (OR = 4.25; 95% CI, 1.44-6.89; p = 0.009) were found as risk factors for influencing infection based on logistic regression analyses. Package per year of cigarette smoking was found statistically significantly higher in patients with infections than patients without infections (p = 0.001). A slight increase in infections, which was of borderline statistical significance (p = 0.07), was observed in patients age over 70. Ciprofloxacin and clarithromycin were the most frequently used agents in treatment. Median survival was 9 months in the patients with infection and 13 months in the 97 patients without infection. Overall survival seemed to be statistically significantly better in patients without infection than patients with infection (p = 0.042) calculated using Kaplan-Meier method. Based on Cox regression analyses; overall survival was not correlated to presence of infection but associated with poor performance status (<= 80) (OR = 2.35; 95% CI, 0.85-8.93; p = 0.03), and usage of corticosteroids (OR=2.68; 95% CI, 0.98-6.72; p = 0.01). The dose of radiation therapy > 5940 cGy (OR = 2.06; 95% CI, 0.72-7.18; p = 0.007) and the absence of response to treatment (OR = 2.45; 95% CI, 0.89-14.23; p < 0.001) were also found to be risk factors for survival. Conclusions: Infections are important causes of morbidity and mortality in lung cancer patients. The control of infection in these patients may improve the survival. Predisposing factors and treatment management approaches in non-small cell lung cancer should be defined carefully. (c) 2004 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [1] Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy
    Moller, Ditte Sloth
    Lutz, Christina Maria
    Khalil, Azza Ahmed
    Alber, Markus
    Holt, Marianne Ingerslev
    Kandi, Maria
    Schmidt, Hjordis Hjalting
    Tvilum, Marie
    Appelt, Ane
    Knap, Marianne Marquard
    Hoffmann, Lone
    RADIOTHERAPY AND ONCOLOGY, 2022, 168 : 234 - 240
  • [2] NEUROPSYCHOLOGICAL EVALUATION OF PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG-CANCER TREATED WITH COMBINATION CHEMOTHERAPY OR RADIOTHERAPY
    KAASA, S
    OLSNES, BT
    MASTEKAASA, A
    ACTA ONCOLOGICA, 1988, 27 (03) : 241 - 246
  • [3] Evaluation of prognostic indices in patients with brain metastases of non-small cell lung cancer treated with stereotactic radiotherapy
    Kaul, D.
    Angelidis, A.
    Budach, V
    Kufeld, M.
    Ghadjar, P.
    Thieme, A.
    Badakhshi, H.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 : 126 - 126
  • [4] Radiotherapy for oligometastatic non-small cell lung cancer patients
    Levy, A.
    Roux, C.
    Mercier, O.
    Issard, J.
    Botticella, A.
    Barlesi, F.
    Le Pechoux, C.
    CANCER RADIOTHERAPIE, 2021, 25 (6-7): : 517 - 522
  • [5] Radiotherapy for elderly non-small cell lung cancer patients
    Kadono, K
    Satoh, H
    Homma, T
    Ohtsuka, M
    Sekizawa, K
    ONCOLOGY REPORTS, 2002, 9 (06) : 1273 - 1276
  • [6] Value of lung perfusion in stage III non-small cell lung cancer patients treated with radiotherapy
    Li, B.
    Wang, Z.
    Yin, Y. O. N. G.
    Yang, G.
    Fu, Z.
    Hu, X.
    Yan, J. I. N. G.
    Zhou, T. A. O.
    EJC SUPPLEMENTS, 2007, 5 (04): : 382 - 382
  • [7] Radiotherapy for non-small cell lung cancer
    Jassem, J
    LUNG CANCER, 2001, 34 : S177 - S180
  • [8] Radiotherapy of non-small cell lung cancer
    Jassem, J
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 207 - 214
  • [9] Radiotherapy of non-small cell lung cancer
    Kleine, P.
    Flentje, M.
    PNEUMOLOGE, 2016, 13 (04): : 241 - +
  • [10] The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy
    Holgersson, Georg
    Sandelin, Martin
    Hoye, Even
    Bergstrom, Stefan
    Henriksson, Roger
    Ekman, Simon
    Nyman, Jan
    Helsing, Martin
    Friesland, Signe
    Brodin, Ola
    Holgersson, Margareta
    Lundstrom, Kristina Lamberg
    Janson, Christer
    Ekberg, Lars
    Morth, Charlotte
    Blystad, Thomas
    Ewers, Sven-Borje
    Loden, Britta
    Bergqvist, Michael
    ANTICANCER RESEARCH, 2012, 32 (04) : 1339 - 1346